Skip to main content
NAII
NASDAQ Life Sciences

Reports Continued Net Loss, Significant Cash Burn, and Repeated Debt Covenant Violations; Seeks New Financing Amid Negative Outlook

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$3.49
Mkt Cap
$21.557M
52W Low
$2.57
52W High
$4.96
Market data snapshot near publication time

summarizeSummary

Natural Alternatives International reported continued net losses, a significant increase in cash used in operations, and repeated debt covenant violations, leading to a negative full-year outlook and an active search for new financing.


check_boxKey Events

  • Continued Net Loss and Increased Cash Burn

    For the six months ended December 31, 2025, the company reported a net loss of $2.844 million (compared to $4.173 million in prior year) and a significant increase in net cash used in operating activities to $10.353 million, up from $3.406 million in the prior year period. Cash and cash equivalents decreased from $12.325 million to $3.753 million over the six-month period.

  • Repeated Debt Covenant Violations

    The company was not in compliance with maximum net loss and fixed charge coverage ratio covenants for the three and six months ended December 31, 2025. It also anticipates non-compliance for the third quarter of fiscal 2026, following a waiver received from Wells Fargo for prior violations.

  • Active Search for New Financing

    Amid ongoing covenant issues, the company is in discussions with Wells Fargo for an additional waiver and is actively pursuing a new asset-based lender to provide increased borrowing capacity and greater flexibility in working capital.

  • Negative Full-Year Guidance

    Management now expects to experience a net loss in the second half of fiscal 2026 and for the full fiscal year, citing declines in customer forecasted sales and delayed new product launches.


auto_awesomeAnalysis

This 10-Q filing reveals a company facing severe financial challenges, despite some improvements in sales and gross profit. The most critical issues are the substantial cash burn from operations, repeated non-compliance with debt covenants, and a revised negative outlook for the full fiscal year. The company's cash and cash equivalents have significantly decreased, and it is actively seeking new asset-based financing, indicating a precarious liquidity position. The recording of a valuation allowance against domestic deferred tax assets further signals management's lack of confidence in realizing future tax benefits from U.S. operations. Investors should be highly concerned about the company's ability to secure new financing and return to profitability.

At the time of this filing, NAII was trading at $3.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.6M. The 52-week trading range was $2.57 to $4.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed NAII - Latest Insights

NAII
Mar 20, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
NAII
Feb 13, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
9